Related Experiment Video
Updated: Mar 27, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Timothy grass pollen therapeutic vaccine: optimal dose for subcutaneous immunotherapy
Javier Sola1, José Alberto da Silva Ferreira2, Javier Dionicio Elera3
1Allergy Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Aims:
To establish the optimal dose of Phleum pratense subcutaneous immunotherapy (SCIT) in patients with allergic rhinoconjunctivitis with/without asthma.
Materials & Methods:
One hundred and fifty-one patients were randomized to receive SCIT 0.25, 0.5, 1.0, 2.0 or 4.0 skin-prick test units (SPT) or placebo. The primary end point was the variation in the concentration of Phleum pratense extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV).
Results:
After 17 weeks, a dose-dependent trend was apparent in the concentration of P. pratense extract needed to produce a positive nasal provocation response. Systemic adverse reactions occurred with 3.2% of administered doses. Grade III (n = 2) and IV (n = 2) events were observed only at the two highest doses.
Conclusion:
P. pratense depot SCIT showed signs of clinical and immunological efficacy by dose-dependently decreasing the allergen sensitization rate. Risk-benefit favored doses below 1.0 SPT units for confirmatory trials.
More Related Videos
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
